Ocugen’s mission is to deliver best-in-class solutions to patients suffering from sight threatening eye diseases. Ocugen has a broad pipeline which includes both clinical stage and pre-clinical programs addressing large areas of unmet medical need. Our programs are focused on activating novel biologic pathways to treat inflammatory, degenerative, and neovascular diseases of the eye and are designed to deliver value over the near, mid and long term.
OCU100 is a recombinant protein based on lens epithelial derived growth factor which has been shown to rescue photoreceptors in well-established models of retinal degeneration. OCU100 has application in degenerative diseases including Retinitis Pigmentosa (RP) and Geographic Atrophy (GA). RP is an inherited disease and those afflicted often go blind by the time they reach their 40’s. GA typically affects older patients and can impact activities of daily living such as reading and driving and can result in loss of independence. Patients with these disorders have no treatment options and represent an area of significant unmet medical need.
OCU200 is a fusion protein based on tumstatin and transferrin which has shown superior performance in head-to-head testing against anti-VEGF treatment in established models of neovascular disease. OCU200 has application in wet age-related macular degeneration (Wet AMD) and Diabetic Retinopathy (DR). Patients with Wet AMD and DR patients can experience a sudden and rapid loss of vision resulting from uncontrolled blood vessel growth. Treatment for Wet AMD and DR is limited to anti-VEGF therapies such as Lucentis, Avastin, and Eyelea. These important drugs have significantly improved the standard of care however they have a limited duration of effect. Recent studies have shown that after 2-4 years of treatment, Wet AMD patients relapse and experience a progressive decline in vision. Therefore there remains a significant unmet need for Wet AMD patients who often live with the disease for 20+ years.
OCU300 is a repurposed drug with an established safety track record in ocular applications being developed under the U.S. Food and Drug Agency’s 505(b)(2) regulatory pathway. In an exploratory observational study, OCU300 was found to improve symptoms in approximately of 90% patients with ocular graft versus host disease. These findings need to be confirmed in a controlled prospective study using objective end points. Currently there is no treatment indicated for ocular graft versus host disease.